Tacalcitol
From Wikipedia, the free encyclopedia
|
Tacalcitol
|
|
| Systematic (IUPAC) name | |
| (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(2R,5R)-5-hydroxy-6-methylheptan-2-yl
]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methyli denecyclohexane-1,3-diol |
|
| Identifiers | |
| CAS number | |
| ATC code | D05 |
| PubChem | |
| Chemical data | |
| Formula | C27H44O3 |
| Mol. mass | 416.64 |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | Topical |
Tacalcitol is a synthetic vitamin D3 analogue that is used to treat psoriasis. Tacalcitol exerts its biological activity by preventing the proliferation of keratinocytes. Tacalcitol is marketed under several names, including Curatoderm and Bonalfa.
[edit] References
- The Merck Index, 12th Edition. 9197
|
||||||||||||||||||||

